CVRX
CVRx, Inc.
CVRX offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CVRX overall, supported by stronger valuation.
CVRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CVRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CVRX PE Valuation
CVRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CVRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CVRX's earnings, revenue and profitability to hold roughly steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over CVRX on the outlook, with more favorable earnings and profitability expectations.
CVRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.00 | -$0.02 |
| Q2 2026 | -$1.97 | +$0.09 |
| Q1 2026 | -$2.01 | +$0.13 |
| Q4 2025 | -$2.04 | +$0.61 |
| Q3 2025 | -$1.98 | +$0.73 |
| Q2 2025 | -$2.06 | +$0.51 |
| Q1 2025 | -$2.14 | +$0.34 |
| Q4 2024 | -$2.65 | -$0.66 |
CVRX is still losing money, but less than at its worst: $2.00 per share over the past year, against $2.71 at its worst in late 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CVRX on earnings quality, reporting a profit while its opponent remains loss making.
CVRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.8M | -5.8% |
| Q2 2026 | $15.7M | +16% |
| Q1 2026 | $14.8M | +20% |
| Q4 2025 | $16M | +4.4% |
| Q3 2025 | $14.7M | +9.8% |
| Q2 2025 | $13.6M | +15% |
| Q1 2025 | $12.3M | +15% |
| Q4 2024 | $15.3M | +36% |
CVRX has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | -11 points |
| Q2 2026 | -83% | +23 points |
| Q1 2026 | -82% | +27 points |
| Q4 2025 | -70% | -2.8 points |
| Q3 2025 | -84% | +14 points |
| Q2 2025 | -106% | +13 points |
| Q1 2025 | -109% | +98 points |
| Q4 2024 | -67% | +19 points |
CVRX's operating margin was −94% last quarter, down 11 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CVRX on profitability, with a higher operating margin.
CVRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11M | -$991K |
| Q2 2026 | -$8.9M | -$899K |
| Q1 2026 | -$12.3M | +$595K |
| Q4 2025 | -$9.8M | -$1.8M |
| Q3 2025 | -$10M | +$443K |
| Q2 2025 | -$8M | +$2.1M |
| Q1 2025 | -$12.9M | -$1.1M |
| Q4 2024 | -$8.1M | -$52K |
CVRX has burned cash in almost every quarter: −$42M over the past year, against −$39M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CVRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CVRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +731K shares |
| 1 year | +4.1% | +1.1M shares |
| 3 years | +31% | +6.4M shares |
| 5 years | +7343% | +26.9M shares |
CVRX has 27M diluted shares, up 4.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CVRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CVRX Net Leverage
CVRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CVRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.1 | Oversold |
| Stochastic | 1.7 | Oversold |
CVRX's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CVRX PE vs Healthcare Sector
CVRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CVRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 56% below |
| 20 week MA | $2.88 | 78% below |
| 50 week MA | $5.38 | 88% below |
| 100 week MA | $7.50 | 92% below |
| 200 week MA | $11.1 | 94% below |
CVRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CVRX on trend strength, trading above more of its moving averages.
CVRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $12.2 | -52% |
| 2022 | $12.2 | $16.7 | +37% |
| 2023 | $16.7 | $31.4 | +88% |
| 2024 | $31.4 | $13.2 | -58% |
| 2025 | $13.2 | $7.42 | -44% |
| 2026 YTD | $7.42 | $0.63 | -92% |
CVRX has finished lower in three of the last five years. It's down 92% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CVRX on returns for 2026, with the stronger performance.